Literature DB >> 3179198

Serial study of phagocytic function in rat bovine serum albumin (BSA) nephritis.

K Kawasaki1, E Yaoita, T Yamamoto, I Kihara.   

Abstract

We have examined the in-vitro role of polymorphonuclear leucocytes (PMNs) and macrophages in the degradation of immune complexes (ICs) at various points during the induction of rat bovine serum albumin (BSA) nephritis. Two types of experiments have been used. In one set (experiment A) preformed 125I-BSA-anti-BSA complexes (which consisted of heterologous (rabbit) antibodies) were incubated with peritoneal macrophages and PMNs from normal and nephritic rats at 37 degrees C for between 1 h and 24 h and the degradation rates of ICs were studied. In the other set (experiment B), homologous ICs prepared from antibodies derived from the sera of nephritic rats were examined using macrophages and PMNs from normal rats. In experiment A, the degradation of heterologous ICs by macrophages was decreased but degradation by PMNs was not decreased if the assays were performed 8 or 9 weeks after injection. Degradation by both macrophages and by PMNs was increased at weeks 10 and 11. In experiment B, the degradation of homologous ICs from the nephritic rats was increased markedly at week 9 and a relationship was observed between both the degradation and antibody titre and the value of the antigen binding capacity of 33% (ABC-33) during the course of nephritis. There was no difference between PMNs and macrophages in their ability to degrade homologous ICs from the nephritic rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179198      PMCID: PMC2013231     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  16 in total

1.  Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease.

Authors:  R H Zubler; U Nydegger; L H Perrin; K Fehr; J McCormick; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

2.  Studies on circulating immune complexes. 3. Factors governing the ability of circulating complexes to localize in blood vessels.

Authors:  C G Cochrane; D Hawkins
Journal:  J Exp Med       Date:  1968-01-01       Impact factor: 14.307

3.  The macrophage receptor for IgG: number and affinity of binding sites.

Authors:  W P Arend; M Mannik
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

4.  Immune complex disease. IV. The nature of the circulating complexes associated with glomerulonephritis in the acute BSA-rabbit system.

Authors:  G R Dreesman; F G Germuth
Journal:  Johns Hopkins Med J       Date:  1972-06

5.  Studies on the micro-quantitation of antibody by the reversed type single radial immunodiffusion.

Authors:  H Nariuchi; M Usui; T Matuhasi
Journal:  Jpn J Exp Med       Date:  1970-02

6.  Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes.

Authors:  J L Van Snick; E Van Roost; B Markowetz; C L Cambiaso; P L Masson
Journal:  Eur J Immunol       Date:  1978-04       Impact factor: 5.532

7.  Bovine serum albumin (BSA) nephritis in rats. I. Experimental model.

Authors:  T Yamamoto; I Kihara; T Morita; T Oite
Journal:  Acta Pathol Jpn       Date:  1978-11

8.  The glomerular deposition of soluble immune complexes prepared with reduced and alkylated antibodies and with intact antibodies in mice.

Authors:  A O Haakenstad; G E Striker; M Mannik
Journal:  Lab Invest       Date:  1976-09       Impact factor: 5.662

9.  Macrophage plasma membrane. II. Studies on synthesis and turnover of protein constituents.

Authors:  R L Nachman; B Ferris; J G Hirsch
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

10.  Association and dissociation of aggregated IgG from rat peritoneal macrophages.

Authors:  D W Knutson; A Kijlstra; L A Van Es
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.